WO2011012217A3 - Copräzipitate umfassend einen phosphodiesterase-5-inhibitor (pde-5-inhibitor) und einen pharmazeutisch verträglichen trägerstoff, ihre herstellung und verwendung - Google Patents

Copräzipitate umfassend einen phosphodiesterase-5-inhibitor (pde-5-inhibitor) und einen pharmazeutisch verträglichen trägerstoff, ihre herstellung und verwendung Download PDF

Info

Publication number
WO2011012217A3
WO2011012217A3 PCT/EP2010/004181 EP2010004181W WO2011012217A3 WO 2011012217 A3 WO2011012217 A3 WO 2011012217A3 EP 2010004181 W EP2010004181 W EP 2010004181W WO 2011012217 A3 WO2011012217 A3 WO 2011012217A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
phosphodiesterase
precipitate
pde
production
Prior art date
Application number
PCT/EP2010/004181
Other languages
English (en)
French (fr)
Other versions
WO2011012217A2 (de
Inventor
Katrin Rimkus
Frank Muskulus
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Priority to EP10730104A priority Critical patent/EP2459174A2/de
Priority to US13/387,276 priority patent/US20120189694A1/en
Priority to EA201270206A priority patent/EA022037B1/ru
Publication of WO2011012217A2 publication Critical patent/WO2011012217A2/de
Publication of WO2011012217A3 publication Critical patent/WO2011012217A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Copräzipitat, umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Copolymer-Trägerstoff bestehend aus 2 oder mehr verschiedenen Acrylsäurederivaten, Verfahren zur Herstellung desselben sowie ein Arzneimittel, umfassend das erfindungsgemäße Copräzipitat, Verfahren zur Herstellung dieses Arzneimittels und die Verwendung dieses Arzneimittels zur Behandlung einer Krankheit, bei der Inhibierung von Phosphodiesterase-5 von therapeutischem Nutzen ist.
PCT/EP2010/004181 2009-07-29 2010-07-08 Copräzipitate umfassend einen phosphodiesterase-5-inhibitor (pde-5-inhibitor) und einen pharmazeutisch verträglichen trägerstoff, ihre herstellung und verwendung WO2011012217A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10730104A EP2459174A2 (de) 2009-07-29 2010-07-08 Copräzipitate umfassend einen phosphodiesterase-5-inhibitor (pde-5-inhibitor) und einen pharmazeutisch verträglichen trägerstoff, ihre herstellung und verwendung
US13/387,276 US20120189694A1 (en) 2009-07-29 2010-07-08 Co-precipitate comprising a phosphodiesterase-5 inhibitor (pde-5-inhibitor) and a pharmaceutically compatible carrier, production and use thereof
EA201270206A EA022037B1 (ru) 2009-07-29 2010-07-08 Копреципитат, включающий ингибитор фосфодиэстеразы-5 (pde-5-ингибитор) и фармацевтически совместимый носитель, его получение и применение

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009035211.2 2009-07-29
DE102009035211A DE102009035211A1 (de) 2009-07-29 2009-07-29 Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung

Publications (2)

Publication Number Publication Date
WO2011012217A2 WO2011012217A2 (de) 2011-02-03
WO2011012217A3 true WO2011012217A3 (de) 2012-04-26

Family

ID=42646808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/004181 WO2011012217A2 (de) 2009-07-29 2010-07-08 Copräzipitate umfassend einen phosphodiesterase-5-inhibitor (pde-5-inhibitor) und einen pharmazeutisch verträglichen trägerstoff, ihre herstellung und verwendung

Country Status (5)

Country Link
US (1) US20120189694A1 (de)
EP (1) EP2459174A2 (de)
DE (1) DE102009035211A1 (de)
EA (1) EA022037B1 (de)
WO (1) WO2011012217A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
WO2014202797A1 (en) * 2013-07-05 2014-12-24 Synthon B.V. Pharmaceutical composition comprising a solid dispersion of tadalafil
EP3082428A4 (de) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5-inhibitorpulverformulierungen und zugehörige verfahren
SI3466951T1 (sl) * 2014-07-23 2022-05-31 Krka, D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038131A1 (en) * 1995-06-02 1996-12-05 Glaxo Group Limited Method of producing a solid dispersion of a poorly water soluble drug
EP1875914A1 (de) * 2006-07-07 2008-01-09 Teva Pharmaceutical Industries Ltd. Feste Zusammensetzungen, die Tadalafil und wenigstens eine Trägersubstanz enthalten

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297866A3 (de) * 1987-07-01 1989-12-13 The Boots Company PLC Arzneimittel
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
UA71629C2 (en) 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
SK287869B6 (sk) 1999-08-03 2012-02-03 Icos Corporation Beta-carboline pharmaceutical compositions
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20080226723A1 (en) * 2002-07-05 2008-09-18 Celonova Biosciences, Inc. Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038131A1 (en) * 1995-06-02 1996-12-05 Glaxo Group Limited Method of producing a solid dispersion of a poorly water soluble drug
EP1875914A1 (de) * 2006-07-07 2008-01-09 Teva Pharmaceutical Industries Ltd. Feste Zusammensetzungen, die Tadalafil und wenigstens eine Trägersubstanz enthalten

Also Published As

Publication number Publication date
WO2011012217A2 (de) 2011-02-03
US20120189694A1 (en) 2012-07-26
EA201270206A1 (ru) 2012-07-30
DE102009035211A8 (de) 2011-05-19
DE102009035211A1 (de) 2011-02-17
EA022037B1 (ru) 2015-10-30
EP2459174A2 (de) 2012-06-06

Similar Documents

Publication Publication Date Title
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008025857A3 (en) New method for the treatment of inflammatory diseases
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
EP2027028A4 (de) Lasche, werkzeug zur herstellung der lasche sowie verfahren zur herstellung der lasche
JO2858B1 (en) Pharmaceutical dosage images
UA104613C2 (en) Alkylamine-substituted dicyanopyridines and amino acid ester prodrugs thereof
GEP20135919B (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
WO2008011131A3 (en) Amide compounds
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2012076466A3 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
WO2007115620A3 (de) Neuartige cyclobutyl-verbindungen als kinase-inhibitoren
WO2007139992A3 (en) ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
AU2009306733C1 (en) Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
EP2479225A4 (de) Neuartige verwendung eines lipolyseenzyms zur formung einer fingerabdruckresistenten beschichtung, substrat mit der in diesem verfahren geformten fingerabdruckresistenten beschichtung und produkte mit dem substrat
IN2012DN01273A (de)
WO2008145842A3 (fr) Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique
UA100544C2 (ru) Гидроксилированный пиримидилциклопентан как ингибитор протеинкиназы акт
WO2011012217A3 (de) Copräzipitate umfassend einen phosphodiesterase-5-inhibitor (pde-5-inhibitor) und einen pharmazeutisch verträglichen trägerstoff, ihre herstellung und verwendung
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
WO2010115125A3 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
UA112764C2 (uk) Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730104

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010730104

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201270206

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13387276

Country of ref document: US